David Calvet Canut։ Efdoralprin Alfa Shows Promise in Alpha 1 Antitrypsin Deficiency
David Calvet Canut, Chief Financial Officer at Rudder Marine Services and Ship Repairs S.L, shared a post on LinkedIn:
”A potential breakthrough for Alpha-1 Antitrypsin Deficiency (AATD) has emerged from Sanofi’s Phase 2 ElevAATe clinical trial.
The investigational treatment, efdoralprin alfa, has shown promising results for adults living with pulmonary emphysema caused by AATD.
Unlike current therapies that rely on donated plasma, efdoralprin alfa is a recombinant protein produced in the laboratory, designed to mimic the natural AAT protein that protects the lungs from inflammatory damage.
This could represent a significant advancement towards a more sustainable, supply-independent treatment option.
Key findings from the ElevAATe trial include:
- Patients achieved normal, stable levels of functional AAT protein, significantly higher than those seen with standard plasma-derived treatment.
- A greater proportion of days were spent at protective protein levels.
- The treatment was well tolerated, with a safety profile comparable to existing therapies.
- It is effective when administered every three to four weeks, potentially offering a more convenient treatment schedule.
Dr. Igor Barjaktarevic, lead investigator at UCLA, noted that achieving normal AAT levels without relying on plasma donations ‘would be a very positive change’ for patients living with Alpha-1.
Efdoralprin alfa has already received both Fast Track and Orphan Drug designations from the FDA, indicating the unmet need this treatment aims to address.
A long-term safety follow-up study (ElevAATe OLE) is now underway.”
Stay updated with Hemostasis Today.
-
Jul 26, 2026, 16:26Novi Yanti Sari: When MPNs Affect the Heart
-
Jul 26, 2026, 16:21Beyond Drugs: Can Museums Become a Medical Prescription?
-
Jul 26, 2026, 14:45Sarah Giorgia Grazia Giannone: An Exciting Chapter in Gene Therapy Research
-
Jul 26, 2026, 14:21Javed Anees: Cerebral Collateral Circulation in Acute Ischemic Stroke
-
Jul 26, 2026, 14:11André Picard։ Canadian Blood Supplies Drop Sharply, Urgent Donor Appeal Issued
-
Jul 26, 2026, 13:54Lorenzo Scalia: New Review Highlights Anticoagulant Strategies for Elderly Patients With Atrial Fibrillation
-
Jul 26, 2026, 13:32Ahmed Kotb: A Practical Guide to Von Willebrand Disease
-
Jul 26, 2026, 12:42Emmanuel J Favaloro: Celebrating Excellence in Scientific Peer Review
-
Jul 26, 2026, 12:20Advancing Sickle Cell Care Through Advocacy – American Society of Hematology